A Single-blind Trial of Disodium Cromoglicate (Intal) in the Treatment of Allergic Bronchial Asthma

DOI Web Site

Bibliographic Information

Other Title
  • 気管支喘息に対するDisodium Cromoglicate(Intal)の効果(Single blind trapdoor trial)
  • キカンシ ゼンソク ニ タイスル Disodium Cromoglicate Intal ノ コウカ Single blind trapdoor trial

Search this article

Abstract

A single-blind trial, in a "trapdoor" type design, of disodium cromoglicate (Intal) was carried out for a period of 7 months in 22 asthmatics suffering from seasonal or perennial attacks, which were not satisfactorily controlled on conventional bronchodilators and low corticosteroid therapy. A definite symptomatic improvement was achieved, described below, in most of the patients throughout the trial period except for a randomly chosen 1 month placebo period in which inactive capsules were substitutioned for Intal: The results showed a complete remission of attacks in 11 cases: marked improvement in a further 6. In addition it was found, that the corticosteroid dose, in 9 patients was reduced and the aerosol bronchodilator requirments decreased in 3 patients during the period on active drug. Of the 22 allergic patients a significant clinical improvement was observed during Intal therapy in 17 patients (77.3%), the eosinophil count in 7 patients during treatment showed values of less than 50% of either that of pretreatment or placebo periods. Five of the 17 patients demonstrated spirometric improvement in the period of Intal therapy. Their maximal mid-expiratory flow (MMF) increased more than 20% as compared with the control period. The corticosteroid requirement was significantly reduced in 9 patients, with complete discontinuation in 4 of these and useful reduction in the remaining 5. In parallel with these objective findings there was symptomatic improvement as shown by daily record cards.

Journal

Details 詳細情報について

Report a problem

Back to top